Sign up to know when
Beyfortus becomes available
at Beyfortus.com
Reference: 1. Beyfortus (nirsevimab-alip). Prescribing Information.
Sanofi .
©2023 Sanofi Pasteur Inc. All rights reserved.
MAT-US-2301344-v1.0-07/2023
SANOFI, Discovery Drive
Swiftwater, Pennsylvania 18370
Beyfortus
™
is
NOW APPROVED!
IMPORTANT SAFETY INFORMATION
Contraindication
Beyfortus is contraindicated in infants
and children with a history of serious
hypersensitivity reactions, including
anaphylaxis, to nirsevimab-alip or to any
of the excipients.
Warnings and Precautions
• Hypersensitivity Including
Anaphylaxis: Serious hypersensitivity
reactions, including anaphylaxis, have
been observed with other human IgG1
monoclonal antibodies. If signs and
symptoms of a clinically signifi cant
hypersensitivity reaction or anaphylaxis
occur, initiate appropriate medications
and/or supportive therapy.
• Use in Individuals with Clinically
Signifi cant Bleeding Disorders: As with
other IM injections, Beyfortus should
be given with caution to infants and
children with thrombocytopenia, any
coagulation disorder or to individuals on
anticoagulation therapy.
Most common adverse reactions with
Beyfortus were rash (0.9%) and injection
site reactions (0.3%).
Please see Brief Summary
on the following pages, and
visit Beyfortus.com to view
the full Prescribing Information.
Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower
respiratory tract disease in
1
:
•
Neonates and infants born
during or entering their fi rst
RSV season
•
Children up to 24 months of age
who remain vulnerable to severe
RSV disease through their
second RSV season
